HAMBURG, Germany U.S. biotechnology company Genentech and German drug maker Evotec hope to develop drugs using Evotec’s drug-discovery platform under a collaboration announced Monday.
Evotec will use its platform combined with its disease biology background to develop drugs for diseases nominated by Genentech. Evotec develops drugs for pain, cancer, inflammation and neurological conditions. Financial terms of the deal were not disclosed.
“We are proud that Genentech, one of the premier biopharmaceutical companies worldwide, has selected Evotec’s scientists and innovative drug-discovery platform to support their research efforts,” Evotec CEO Werner Lanthaler said in a statement. “We look forward to working closely with Genentech’s scientists and achieving success together.”